3ntg: Difference between revisions
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ntg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ntg OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3ntg RCSB], [http://www.ebi.ac.uk/pdbsum/3ntg PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ntg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ntg OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3ntg RCSB], [http://www.ebi.ac.uk/pdbsum/3ntg PDBsum]</span></td></tr> | ||
</table> | </table> | ||
== Function == | |||
[[http://www.uniprot.org/uniprot/PGH2_MOUSE PGH2_MOUSE]] Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.<ref>PMID:12925531</ref> <ref>PMID:20463020</ref> <ref>PMID:20810665</ref> <ref>PMID:21489986</ref> | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == |
Revision as of 19:00, 24 December 2014
Crystal structure of COX-2 with selective compound 23d-(R)Crystal structure of COX-2 with selective compound 23d-(R)
Structural highlights
Function[PGH2_MOUSE] Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.[1] [2] [3] [4] Publication Abstract from PubMedIn this Letter, we provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors. During the course of our structure-based drug design efforts, we discovered two distinct binding modes within the COX-2 active site for differently substituted members of this class. The challenge of a undesirably long human half-life for the first clinical candidate 1t(1/2)=360h was addressed by multiple strategies, leading to the discovery of 29b-(S) (SC-75416) with t(1/2)=34h. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life.,Wang JL, Limburg D, Graneto MJ, Springer J, Hamper JR, Liao S, Pawlitz JL, Kurumbail RG, Maziasz T, Talley JJ, Kiefer JR, Carter J Bioorg Med Chem Lett. 2010 Jul 24. PMID:20709553[5] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Mus musculus
- Prostaglandin-endoperoxide synthase
- Carter, J C
- Graneto, M J
- Kiefer, J R
- Limburg, D
- Talley, J J
- Wang, J L
- Cox-2
- Cox2
- Cyclooxygenase-2
- Dioxygenase
- Disulfide bond
- Endoplasmic reticulum
- Fatty acid biosynthesis
- Glycoprotein
- Heme
- Iron
- Lipid synthesis
- Membrane
- Metal-binding
- Microsome
- Oxidoreductase
- Peroxidase
- Pgh2s-2
- Phosphoprotein
- Prostaglandin biosynthesis